Brain Submission Process

This page was created by checking current Brain general instructions, OUP ScholarOne submission guidance, Brain reporting-guideline requirements, official and generic pages for Brain submission process queries, and Manusights pre-submission reviews from authors deciding between Brain, Brain Communications, Journal of Neurology, Journal of Neuroscience, The Lancet Neurology, and disease-specific neurology journals. We also reviewed the 100 most recent Brain research papers used when this guide was built, then compared those public papers with recent Manusights work reviews for neurology and translational neuroscience manuscripts.

Manusights internal analysis identifies one recurring Brain-failure pattern: the paper has either clinical relevance without mechanistic explanation or strong experimental neuroscience without a clear neurology readership case. In Manusights review data for Brain-targeted submissions, 31.8% of manuscripts showed this mechanism-versus-description mismatch before upload. Official and generic pages mostly cover OUP upload mechanics, article formatting, reporting guidelines, and journal metrics.

Use this guide for what editors screen for after upload: whether the title, structured abstract, first figure, reporting checklist, and cover letter make a Brain-level disease-mechanism argument visible.

Source limitation: we did not test a private ScholarOne Brain submission account. Portal mechanics are based on public OUP and Brain materials. Timing estimates are directional and can vary by editor, article type, reviewer availability, and reporting-compliance checks.

This page is about workflow after upload.

Use it when you want to understand:

• what happens once the manuscript enters the ScholarOne/OUP system

• what editors are really screening for first

• how to interpret quiet periods, triage, and review-stage slowdowns

• what usually causes a paper to stop before full review matters

If you still need to decide whether the package is ready, that belongs on the submission-guide page.

The process usually feels cleaner when the manuscript already arrives with:

• a broad-enough neurology audience case

• a mechanistic or disease-biology consequence that is visible early

• methods and supplement stable enough for a hard editorial read

• a cover letter that explains why this belongs in Brain specifically

If those pieces are soft, the workflow can feel harsher than authors expect because the system exposes weakness early.

If you want a fast read on those risks before upload, use the Brain manuscript fit check to check whether the draft presents a Brain-level mechanism, readership case, and submission package.

The first stage is not mainly testing technical compliance.

It is testing whether:

• the paper belongs in Brain rather than a narrower neurology or neuroscience journal

• the mechanistic and neurological consequence is strong enough to justify reviewer time

• the evidence package supports the breadth of the claim

• the manuscript looks complete enough for serious evaluation

That is why fast rejection here often means "not broad or mechanistic enough for this journal," not "bad science."

Authors should think in stages:

• the earliest period is mostly fit, mechanism, and package-stability judgment

• movement into fuller review usually means the hardest editorial screen has been cleared

• later slowdowns often reflect reviewer alignment or evidentiary questions rather than admin delay

The practical point is that the real risk sits early. Once the paper survives that first triage read, the process becomes more about how well the evidence carries the mechanistic claim.

Brain follows standard OUP/ScholarOne submission requirements:

• manuscript file (Word preferred) with embedded figures

• separate high-resolution figure files

• cover letter

• supplementary material as separate files

• conflict of interest disclosures

• patient consent documentation (mandatory for case studies)

• data availability statement

What's specific to Brain:

Word limits are strict. Original Articles are limited to 5,000 words (excluding abstract, references, tables, and figure legends). Reviews can be longer with editorial approval. These limits are tighter than many neuroscience journals.

Structured abstracts are required. The format is Background, Methods, Results, and Discussion (not Conclusions). This differs from most medical journals that use Background/Methods/Results/Conclusions.

Patient consent is taken seriously. Any case report, case series, or study using identifiable patient data requires explicit consent documentation. Brain will ask for this during review if it's not provided upfront.

Before you upload, running through Brain submission readiness check can catch formatting gaps and strengthen the mechanistic framing.

Initial Quality Check: ScholarOne package and reporting files

The editorial office checks whether the manuscript, figures, supplementary files, ethics language, data availability statement, conflicts, trial registration where relevant, and reporting checklist are complete enough to enter editorial assessment. This is where a technically complete but inconsistent package can lose time before the science is even evaluated.

Editorial Assignment: mechanistic neurology triage

The editor screens whether the paper explains a neurological disease mechanism rather than merely describing an association, cohort, model, or marker. The title, structured abstract, first figure, and cover letter need to point to the same Brain-level claim.

Peer Review: single-anonymous external assessment

If the paper clears triage, Brain can send it to external reviewers under single-anonymous review. Reviewers usually test whether the manuscript components support the claimed mechanism: study design, controls, cohort definition, statistics, figure logic, reporting checklists, data availability, and clinical or disease relevance.

Final Decision: revise, reject, or reroute

The final decision reflects both reviewer comments and editor judgment about whether the paper belongs in Brain. A revision request is not only a request for more detail; it is usually a test of whether the manuscript can make its mechanistic and neurology-readership case more cleanly.

• Clinical cohort without disease-mechanism proof. The manuscript is clinically relevant, but the abstract and first figure still describe association, prediction, or burden rather than a disease mechanism that changes neurological understanding.

• Strong model biology without a Brain readership case. The animal, cell, circuit, or molecular work is credible, but the title, abstract, references, and cover letter do not prove why the finding belongs in a neurology journal rather than a broader neuroscience venue.

• Reporting package that weakens trust. The ethics statement, data availability language, cohort definition, statistical endpoint, figure legends, and supplementary files do not match the same central claim, so the PDF looks less mature than the science.

Across the 100 recent Brain research papers reviewed when this guide was built, the common first-screen pattern was not "more detail everywhere." It was alignment: title, structured abstract, first figure, methods, reporting checklist, and cover letter all making the same disease-mechanism argument. The review tells you whether your paper has that alignment before upload. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on unpublished manuscripts.

Check whether your Brain manuscript has clinical relevance without mechanism →

Check whether your Brain manuscript looks like neuroscience without a neurology readership case →

Check your Brain reporting package before ScholarOne upload →

This guide tells you how Brain's public submission process works; the review tells you whether your paper's title, abstract, figures, methods, reporting files, and cover letter are coherent enough for that process. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on unpublished manuscripts.

1. Is there a mechanistic contribution, not just a clinical observation? Brain wants papers that explain disease mechanisms. A large cohort study showing that biomarker X predicts outcome Y in Parkinson's disease is descriptive. A study showing that biomarker X reflects a specific degenerative process and explaining why that process predicts outcome Y is mechanistic. Brain wants the second paper.

2. Is the neurological disease relevance front and center? Pure neuroscience papers about synaptic plasticity or neural circuitry without direct connection to neurological disease belong at Journal of Neuroscience or Neuron. Brain wants the disease angle to be obvious from the title and abstract.

3. Are the methods appropriate for the claim? Brain's academic editors are practicing researchers who know what controls and sample sizes are standard in each subfield. Underpowered imaging studies, genetic analyses without proper correction for multiple comparisons, and animal models without behavioral validation are flagged quickly.

4. Does the paper span basic and clinical neurology? The strongest Brain papers often combine clinical cohort data with experimental validation, or use patient-derived materials to test mechanistic hypotheses. Papers that sit entirely in one domain (purely clinical or purely experimental) face a higher bar.

Several things repeatedly make the process go badly:

The science may be solid, but if the manuscript mainly catalogs a phenomenon rather than explaining it, editors often see that quickly.

Brain is broad within neurology. If the natural readership is mostly one subspecialty niche, the paper starts to look like a better fit elsewhere.

If controls, sample logic, or analytical framing still look soft on the first read, editors have less reason to invest reviewer time.

If the title, abstract, and first figure do not make the consequence obvious, the editor has less reason to keep carrying the paper forward.

The strongest Brain submissions usually have a recognizable profile:

• one important neurological question

• one stable mechanistic conclusion

• one broad audience case for neurologists

• one first-read package that feels methodologically secure

• one cover letter that sounds like judgment, not branding

This is why the process is not just administrative. The package itself tells the editor whether the authors understand the journal.

One common failure mode is a letter that promises a broader or more practice-relevant paper than the manuscript actually delivers. Editors usually catch that mismatch immediately.

If the key neurological message takes too long to emerge, the editor may conclude the paper is too slow for Brain even if the science is real.

A Brain submission loses force when the title, abstract, supplement, and declarations still look provisional. Package instability often gets interpreted as scientific or strategic instability.

The abstract and cover letter should reinforce each other.

The abstract should:

• state the central finding plainly

• make the neurological consequence visible

• avoid overselling before the evidence can support the promise

The cover letter should:

• explain why neurologists should care

• clarify what changed mechanistically

• give the editor a clean reason to send the paper out

If those two pieces describe different levels of ambition, the package weakens immediately.

The final hour before a serious Brain submission should not be spent rewriting the science. It should be spent checking package consistency.

That usually means checking:

• the title, abstract, and cover letter make the same mechanistic promise

• the key figure supports the same promise the abstract is making

• ethics, disclosures, and funding language match the manuscript

• supplementary analyses do not quietly weaken the main story

• author order and affiliations are final

If those pieces still feel fluid, the submission often looks less mature than the science deserves.

Across neurology and translational neuroscience manuscripts targeting Brain, three failure patterns explain why otherwise serious packages stall after ScholarOne upload. Brain's public instructions cover the online submission site, cover-letter requirements, ORCID expectations, file conversion to review PDF, reporting requirements, and duplicate-publication disclosure. The editorial question underneath those mechanics is narrower: whether the manuscript reads as a Brain paper from the first pass, with disease relevance, mechanistic consequence, and manuscript-package maturity visible in the title, structured abstract, first figure, methods, reporting checklist, cover letter, references, and supplementary files.

Clinical-importance framing where the abstract never proves a disease mechanism

Across neurology manuscripts targeting Brain, the most common failure pattern is a draft whose abstract and cover letter lead with disease burden, patient need, cohort size, or unmet clinical urgency, while the figures do not yet prove a mechanism that changes how the neurological disease is understood. This can happen in biomarker, imaging, genetics, neurodegeneration, neuroinflammation, epilepsy, movement-disorder, stroke, and cognitive-neurology papers.

The title promises a Brain-level disease-biology contribution, but the first figure shows association, stratification, or prediction rather than a mechanistic consequence. The methods section may be careful and the cohort may be valuable, yet the manuscript still reads like a clinical-characterization paper because the causal or disease-biology link is left to the discussion.

Brain editors can see this mismatch quickly because the review PDF puts the title, structured abstract, figures, and captions into one first-read package. If the structured abstract claims mechanism but the main result is an odds ratio, imaging cluster, risk score, or transcriptomic signature without validation, the paper starts to look better suited to Brain Communications, Journal of Neurology, Neurology, Annals of Neurology, or a disease-specific journal depending on scope and evidence depth.

The practical fix is not louder language in the cover letter. It is aligning the abstract, first figure, methods, controls, references, and supplementary analyses around the same mechanistic claim, then naming what disease process the manuscript explains that the current literature could not explain before.

Experimental-neuroscience package without a Brain-specific neurology readership case

Across translational neuroscience manuscripts targeting Brain, the opposite pattern appears just as often: the experimental biology is strong, the controls are thoughtful, and the figures may be technically persuasive, but the manuscript never proves why the work belongs in Brain rather than Journal of Neuroscience, Nature Neuroscience, eLife, Cell Reports, or a methods and mechanism venue.

The title names a pathway, cell type, circuit, assay, or animal model, while the abstract treats neurological disease as context rather than as the load-bearing audience case. The first figure starts with mechanism, the methods section reads like basic neuroscience, and the cover letter later explains clinical relevance as an implication.

That structure weakens a Brain submission because the journal's readership is organized around neurological disease, not only around elegant mechanism. A Brain-targeted paper needs the disease consequence to be visible early enough that a neurology editor can explain why this manuscript matters to clinicians and disease researchers as well as to neuroscientists.

The manuscript components that usually need repair are concrete: the title should name the disease-relevant consequence, the structured abstract should state the patient or disease-biology connection before the conclusion, the first figure should anchor the biological claim to the neurological problem, the methods should justify model choice against the disease question, and the references should show command of the neurology literature rather than only the mechanism literature.

Without that alignment, the paper can be good science and still be a weaker Brain submission than a better-routed specialist-journal submission.

Reporting package maturity that makes the editor distrust the first-read PDF

Across Brain-targeted manuscripts, a third pattern is less conceptual but still damaging: the science may be close, yet the submission package looks unfinished when the editor checks the PDF, reporting checklist, ethics language, data availability statement, author disclosures, figure files, supplementary methods, and cover letter together.

Brain's instructions require online submission, cover-letter material, review-PDF generation, ORCID information, duplicate-publication disclosure when overlap exceeds the stated threshold, and publication-standard figure and multimedia handling. Those requirements are not merely administrative. They shape whether the package feels ready for expert review.

The failure mode is usually inconsistency. The structured abstract promises a primary mechanistic endpoint that the methods define differently. A key supplementary table carries the real cohort description, while the main methods section is too thin. The reporting checklist mentions exclusions or subgroup decisions that the results section never explains. Figure legends omit acquisition or quantification details needed to trust the main claim. The cover letter frames the paper as broad neurology, while the references and supplement reveal a narrower technical story.

In that situation, Brain, Brain Communications, Journal of Neuroscience, The Lancet Neurology, Neurology, and disease-specialist journals become routing choices rather than prestige steps. The fix is to audit the manuscript as one evidence package: title, structured abstract, first figure, methods, reporting checklist, cover letter, references, and supplement should all support the same Brain-level disease-mechanism claim before upload.

Check whether your Brain manuscript is submission-ready →

This is one common way to weaken trust. The problem is not only overclaiming. It is making the first read unstable.

Editors need a reason the paper belongs in Brain. A letter that mainly says the work is exciting or high impact without explaining the audience case is usually weaker than authors think.

A submission can satisfy the portal while still looking conceptually unsettled. If the package logic still feels provisional, the process weakens before review starts.

• Brain journal page

• Brain Submission Guide

• Is Brain a Good Journal?

• Brain Review Time

• Journal of Neuroscience Submission Guide